logo

Myokardia Inc (MYOK)



Trade MYOK now with
  Date
  Headline
8/21/2019 8:36:37 AM MyoKardia Begins Dosing In Phase 1 Clinical Study Of MYK-224 For Hypertrophic Cardiomyopathy
5/13/2019 6:24:17 AM Wedbush Reiterates MyoKardia Inc (MYOK) At Outperform With $87 Price Target
3/26/2019 8:59:01 PM MyoKardia Prices Public Offering Of 4.925 Mln Shares At $51.00/shr
2/28/2019 8:36:21 AM MyoKardia Q4 Net Loss $15.7 Mln Or $0.39/Shr Vs Loss Of $10.1 Mln Or $0.28/Shr Last Year
1/2/2019 8:05:54 AM MyoKardia Regains Worldwide Rights To All Programs Covered Under License, Collaboration Agreement With Sanofi
12/11/2018 8:35:28 AM MyoKardia Reports Positive Data From Phase 1b Single-Ascending Dose Clinical Trial Of MYK-491
11/13/2018 7:24:15 AM Wedbush Reiterates MyoKardia Inc (MYOK) At Outperform With $77 Price Target
11/12/2018 7:33:13 AM MyoKardia Presents Preclinical Evidence Of Mavacamten’s Novel Effect On Diastolic Compliance
11/9/2018 8:55:32 AM Wedbush Is Increasing MyoKardia Inc (MYOK) FY18 Estimate To -1.97 From -2.20
11/9/2018 8:55:13 AM Wedbush Is Raising MyoKardia Inc (MYOK) Q4 18 Estimate To -0.58 From -0.65
11/9/2018 8:54:57 AM Wedbush Is Increasing MyoKardia Inc (MYOK) Q3 18 Estimate To -0.39 From -0.57
11/9/2018 8:54:32 AM Wedbush Reiterates MyoKardia Inc (MYOK) At Outperform With $77 Price Target
10/25/2018 12:03:52 AM MyoKardia Announces Initiative To Create Hypertrophic Cardiomyopathy Patient Community In Collaboration With 23andMe
8/9/2018 9:50:09 AM Wedbush Is Increasing MyoKardia Inc (MYOK) FY18 Estimate To -2.22 From -2.45
8/9/2018 9:49:51 AM Wedbush Is Raising MyoKardia Inc (MYOK) Q4 18 Estimate To -0.64 From -0.72
8/9/2018 9:49:37 AM Wedbush Is Raising MyoKardia Inc (MYOK) Q3 18 Estimate To -0.57 From -0.66
8/9/2018 9:49:13 AM Wedbush Reiterates MyoKardia Inc (MYOK) At Outperform With $77 Up From $64 Price Target